Navigation Links
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Date:8/19/2007

tively prevent or treat ARF.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics based on its proprietary gene discovery science and technology, with an initial focus on drug candidates that work through the recently discovered natural mechanism in the cell known as RNA interference, or RNAi, for the treatment of diseases associated with oxidative stress. Quark believes that its proprietary target gene discovery platform, BiFAR(TM), combined with its ability to design and successfully deliver synthetic molecules of the new class of RNAi therapeutics known as small-interfering RNA, or siRNA, to specific organs in the body, enables the Company to rapidly develop drug candidates. Quark has two internally discovered and developed lead candidates: RTP801i-14 in Phase 1 clinical trial for the treatment of wet age-related macular degeneration, and AKIi-5 for the prevention of acute renal failure. The Company has licensed siRNA drug candidates designed to inhibit Quark's proprietary target gene RTP801, including RTP801i-14, to Pfizer on an exclusive worldwide basis. Quark has, in addition, a product candidate portfolio of RNAi therapeutics based on novel targets and therapeutic concepts discovered using BiFAR(TM) and designed for the treatment of oxidative stress associated diseases of the inner ear, lungs and additional organs of the body.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available on the Company website at http://www.quarkpharma.com.

Forward-looking statement

Various statements in this release concerning the Company's future expectations, plans and prospects, including its intention to publicly offer shares of its common stock, constitute forward-lookin
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)MADISON, N.J., Dec. 3 A genetic variation that may indicate a patient,s risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is
(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 1Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 2Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 3Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 4Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 5Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 6Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 7Stent Studies Tied to Rapid Changes in Use 52992 1Stent Studies Tied to Rapid Changes in Use 52992 2DURECT to Present at the BMO Capital Markets Healthcare Conference 52990 1DURECT to Present at the BMO Capital Markets Healthcare Conference 52990 2
...27 A doctor who is,internationally recognized for...cally for research on DHA, an omega-3 fatty acid, ...d for outstanding achievement in the field,of mate...as among the first to report that infants,receivin...oic acid) levels,than formula-fed infants and the ...
...ur Years of Treatment Presented at ICAAC/IDSA,2008...ough,Corporation (NYSE: SGP ) today reported a da...tional CCR5 receptor antagonist, demonstrated,sust...nts and was well,tolerated through up to four year... patients. Vicriviroc was administered once-daily ...
Other Medicine Technology:March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
Breaking Medicine News(10 mins):Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Are angry women more like men? 2
...r the first time, a new study has looked into how ...derstand and retell a script-based story. , When...ing to a restaurant, we remember the kinds of acti...are listening to a story that takes place at a res...
...sudden loss of T cells -- white blood cells crucia...he onset of AIDS, according to a study published i...ology by a team of researchers at Tulane National ... current thinking regarding AIDS, namely that a su...
...NGTON, Sept. 21 Business Roundtable and,the Ameri...h the,Roundtable,s Partnership for Disaster Respon...the business community to contribute its vast,reso...ement is timed with National Preparedness Month, a...
...ned National Security Facility to Offer EHR-Enhanc...tration/Billing for 8,500 Employees ...ghlights Growing Trend of Computer-Enhanced Onsite...linical software and,information solutions that ph...
...IEGO, Sept. 21 ChemDiv, Inc. (San Diego) announce...tute (CDRI, Moscow) is,undertaking a partnership w...the Russian Academy of Medical Sciences, the US De...state cancer,(PRC). The partnership will operate u...
...WOOD, Colo., Sept. 21 Baxa Corporation, a leading...elivery in hospital,pharmacies, announces the addi.... These agreements -- with Magallan Pharma Trading... South,America and the Caribbean. "Global markets...
Other Medicine News:Health News:Progression of SIV infection in monkeys raises 2Health News:Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nation's Preparedness for Disasters 2Health News:Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nation's Preparedness for Disasters 3Health News:Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nation's Preparedness for Disasters 4Health News:Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center 2Health News:Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center 3Health News:Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center 4Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 2Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 3Health News:Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic 2
DNA Engine Thermal Cycler Chassis, w/96-well block & motorized lid
DNA Engine Thermal Cycler Chassis
MBS Satellite Thermal Cycler 0.5ml
MBS Satellite Thermal Cycler 0.2ml
Medicine Products: